AMAmanda Marie Moore

Amanda Marie Moore

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amanda Marie Moore has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Associations Between Liver Biomarkers and Clinical Outcomes in Patients With Primary Sclerosing Cholangitis: A Retrospective Real‐World Study

    by Jun Xu, Yunhao Liu, Amanda M. Moore, Zhiwei Zhang, E. Susan Amirian, Catherine Frenette, Stephanie Watkins, William T. Barchuk, Lisa Boyette, Christopher L. Bowlus, et al.

    Background and Aims: This retrospective observational study assessed whether liver biomarker levels and their temporal changes can predict clinical outcomes in patients with primary sclerosing cholangitis (PSC). Approach and Results: Adults with any cholangitis diagnosis in the TriNetX Dataworks‐USA network during the study period (2011–2021) were identified; those with ≥ 2 PSC‐specific ICD‐10 codes (K83.01; introduced in 2018) ≥ 30 days apart were included ( N = 2373). Excluding 829 patients with clinical outcomes at baseline, a total of 1544 patients were included in the PSC‐related outcome analysis population. Associations between biomarker levels and clinical outcomes were assessed using multivariate Cox regression models, whereas case–control analyses using logistic regression models evaluated associations between percentage change in biomarker levels (baseline to 6–12 months pre‐outcome) and clinical outcomes. Adjusted hazard ratios and odds ratios (aORs) were calculated for quartiles (Q) 2–4 versus Q1 for ALP, ALT, AST and total bilirubin; and for Q1–Q3 versus Q4 for albumin. Some baseline and pre‐outcome biomarker levels were associated with clinical outcomes. However, most significant findings were associations between changes in biomarker levels over time and clinical outcomes (aOR), including increases in ALP (Q4: 2.78) and AST (Q4: 1.70), decreases in albumin (Q1: 2.48; Q2: 1.89) and cirrhosis; increases in ALP (Q4: 11.45) and bilirubin (Q4: 3.30), decreases in albumin (Q1: 5.88) and hepatic decompensation; increases in ALP (Q4: 2.20) and bilirubin (Q2: 0.55; Q3: 0.46), decreases in albumin (Q1: 3.20) and the composite outcome of other or unspecified cirrhosis, liver transplant or death. Conclusions: Monitoring temporal changes in routine liver biomarker levels has clinical utility for predicting the risk of PSC‐related clinical outcomes.

  • Shift in first-line therapies for United States Veterans Affairs (VA) patients with chronic lymphocytic leukemia (CLL)

    by Christopher Raymond Frei, Kellie Ryan, Grace Oby Obodozie-Ofoegbu, Amanda Marie Moore, Chengwen Teng, Kana Tai Lucero, Laura Dean Davis, Xavier Francisco Jones, Zohra Nooruddin

  • Open Access

    Health Equity in Patients Receiving Durvalumab for Unresectable Stage III Non-Small Cell Lung Cancer in the US Veterans Health Administration

    by Amanda M Moore, Zohra Nooruddin, Kelly R Reveles, Jim M Koeller, Jennifer M Whitehead, Kathleen Franklin, Paromita Datta, Munaf Alkadimi, Lance Brannman, Ion Cotarla, et al.

    Real-world evidence is limited regarding the relationship between race and use of durvalumab, an immunotherapy approved for use in adults with unresectable stage III non-small cell lung cancer (NSCLC) post-chemoradiotherapy (CRT). This study aimed to evaluate if durvalumab treatment patterns differed by race in patients with unresectable stage III NSCLC in a Veterans Health Administration (VHA) population. This was a retrospective analysis of White and Black adults with unresectable stage III NSCLC treated with durvalumab presenting to any VHA facility in the US from January 1, 2017, to June 30, 2020. Data captured included baseline characteristics and durvalumab treatment patterns, including treatment initiation delay (TID), interruption (TI), and discontinuation (TD); defined as CRT completion to durvalumab initiation greater than 42 days, greater than 28 days between durvalumab infusions, and more than 28 days from the last durvalumab dose with no new durvalumab restarts, respectively. The number of doses, duration of therapy, and adverse events were also collected. A total of 924 patients were included in this study (White = 726; Black = 198). Race was not a significant factor in a multivariate logistic regression model for TID (OR, 1.39; 95% CI, 0.81-2.37), TI (OR, 1.58; 95% CI, 0.90-2.76), or TD (OR, 0.84; 95% CI, 0.50-1.38). There were also no significant differences in median (interquartile range [IQR]) number of doses (White: 15 [7-24], Black: 18 [7-25]; P = .25) or median (IQR) duration of therapy (White: 8.7 months [2.9-11.8], Black: 9.8 months [3.6-12.0]; P = .08), although Black patients were less likely to experience an immune-related adverse event (28% vs. 36%, P = .03) and less likely to experience pneumonitis (7% vs. 14%, P < .01). Race was not found to be linked with TID, TI, or TD in this real-world study of patients with unresectable stage III NSCLC treated with durvalumab at the VHA.